Electra Therapeutics (NASDAQ:ETRA) Director Carl Gordon Purchases 71,367 Shares of Company Stock

Electra Therapeutics, Inc. (NASDAQ:ETRA) Director Carl Gordon purchased 71,367 shares of Electra Therapeutics stock in a transaction that occurred on Wednesday, November 4th. The shares were purchased at an average cost of $7.53 per share, with a total value of $537,393.51. Following the transaction, the director directly owned 5,189,871 shares of the company’s stock, valued at $39,079,728.63. This represents a 1.39% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Electra Therapeutics Price Performance

Shares of NASDAQ ETRA opened at $7.35 on Friday. Electra Therapeutics, Inc. has a twelve month low of $6.86 and a twelve month high of $15.50.

Analysts Set New Price Targets

ETRA has been the subject of a number of research analyst reports. JPMorgan Chase & Co. initiated coverage on Electra Therapeutics in a research note on Thursday, October 22nd. They issued an “overweight” rating and a $36.00 price target for the company. HC Wainwright started coverage on Electra Therapeutics in a report on Monday, October 26th. They set a “buy” rating and a $30.00 price target on the stock. Evercore started coverage on Electra Therapeutics in a research report on Tuesday, October 13th. They set an “outperform” rating and a $36.00 price objective on the stock. TD Cowen started coverage on Electra Therapeutics in a research report on Tuesday, October 13th. They set a “buy” rating on the stock. Finally, Zacks Research upgraded Electra Therapeutics to a “hold” rating in a report on Wednesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Electra Therapeutics currently has an average rating of “Buy” and a consensus price target of $33.50.

Electra Therapeutics News Summary

Here are the key news stories impacting Electra Therapeutics this week:

• Positive Sentiment: Director Carl Gordon, associated with OrbiMed Advisors, reported purchases totaling 472,571 shares across November 3–5, worth approximately $3.6 million. The transactions increased his reported position, a sign of insider confidence. SEC filing
• Neutral Sentiment: Management plans to present at the Jefferies Global Healthcare Conference in London on November 18. The announcement provides an opportunity to discuss the company, but no new clinical or business developments were included. Conference announcement

About Electra Therapeutics

Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function.

Electra’s lead investigational product is ELA026, an antibody targeting SIRP?, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.